Hospital days in risperidone-treated patients

Canadian Journal of Psychiatry

Volumn 44, Issue 9, 1999, Pages 909-913

  Dickson, Ruth A ^a,d   Dalby, J Thomas ^b   Addington, Donald ^a   Williams, Richard ^c   McDougall, Gerald M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Calgary General Hospital   (Canada)

Author keywords

Hospital days; Outcomes; Risperidone; Schizophrenia

Indexed keywords

RISPERIDONE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTPATIENT CARE; PRESCRIPTION; SCHIZOPHRENIA;

EID: 0033460266     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674379904400907     Document Type: Article

References (16)

1. Williams R, Dickson RA. Economics of schizophrenia. Can J Psychiatry 1995;40 Suppl 2:60-67.
2. Wasylenski DA. The cost of schizophrenia. Can J Psychiatry 1994;39 Suppl 2:65-69.
3. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994;55(9 Suppl B):161-5.
4. Remillard AJ, Johnson JA. A pharmacoeconomic evaluation of clozapine in 1 patient. Can J Hospital Pharmacy 1993;46:115-8.
5. Dickson RA, Williams R, Dalby JT, Warden SJ. Hospital days in clozapine treated patients. Can J Psychiatry 1998;43:945-8.
6. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, and others. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veteran Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Medicine 1997;337.809-15.
7. Chouinard G, Jones B, Remington G, Bloom W, Addington D, MacEwan GW, and others. A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
8. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
9. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the 5 dimensions of schizophrenia derived by factor analysis; combined results of the North American trials. J Clin Psychiatry 1997;58:538-46.
10. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clinical Therapeutics 1993;15:917-26.
11. Lindstrom E, Eriksson B, Hellgren A, von Knorring L, Eberhard G. Efficacy and safety of risperidone in the long term treatment of patients with schizophrenia. Clinical Therapeutics 1995;17:402-12.
12. Albright PS, Livingstone S, Keegan D, Ingham M, Shrikhande S, LeLorier J. Reduction if healthcare resource utilization and costs following the use if risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan Health linkable databases. Clin Drug Invest 1996;5:289-99.
13. Guest JF, Hart WM, Cookson RD, Lindstrom E. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. British Journal of Medical Economics 1996; 10:59-67.
14. Viale G, Mechling L, Maislin G, Durkin M, Engelhart L, Lawrence BJ. Impact of risperidone on the use of health-care resources. Psychiatr Serv 1997;48:1153-9.
15. Essock SM, Hargreaves WA, Covel NH, Goethe J. Antipsychotics in research and clinical settings. Psychopharmacol Bull 1996;32:683-97.
16. Luchins DJ, Hanrahan P, Shinderman M, Lagios L, Fichtner CG. Initiating clozapine treatment in the outpatient clinic: service utilization and cost trends. Psychiatr Serv 1998;49:1034-8.